SIGLEC7 Antibody

What is SIGLEC7 and what cellular populations express it?

Sialic acid binding Ig-like lectin 7 (Siglec-7), also known as CD328 or p75/AIRM-1, is a member of the Siglec family of glycan-recognition proteins. It functions as an inhibitory receptor primarily expressed on natural killer (NK) cells and monocytes . Structurally, Siglec-7 is a type-I transmembrane protein consisting of three extracellular immunoglobulin-like domains that comprise an N-terminal V-set domain and two C2-set domains . Understanding this expression pattern is critical for designing experiments targeting specific immune cell populations.

What are the recommended applications and dilutions for SIGLEC7 antibody use?

SIGLEC7 antibodies can be utilized across multiple applications with specific recommended dilutions for optimal results. For Western Blot (WB) applications, a dilution range of 1:500-1:2000 is recommended. For Immunohistochemistry (IHC), researchers should use a dilution between 1:50-1:500 . Additionally, SIGLEC7 antibodies have been validated for Immunofluorescence (IF) and ELISA applications. It is important to note that optimal dilution may be sample-dependent, and researchers should consider titrating the antibody in each testing system to obtain optimal results .

What tissue samples have been validated for SIGLEC7 antibody reactivity?

SIGLEC7 antibodies have demonstrated positive reactivity in specific tissues and cell types. Western blot applications have successfully detected SIGLEC7 in human placenta tissue, human liver tissue, U-937 cells, and mouse placenta tissue . For immunohistochemistry, positive detection has been observed in human tonsillitis tissue, human liver tissue, and human placenta tissue . When performing IHC, antigen retrieval is suggested with TE buffer pH 9.0, with an alternative option of using citrate buffer pH 6.0 for optimization purposes.

What storage conditions are required for maintaining SIGLEC7 antibody efficacy?

For optimal preservation of antibody activity, SIGLEC7 antibodies should be stored at -20°C, where they remain stable for one year after shipment. The typical storage buffer consists of PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . Importantly, aliquoting is generally unnecessary for -20°C storage, simplifying laboratory handling. Some antibody preparations may contain 0.1% BSA, particularly in smaller volume formats (20μl sizes) . Researchers should monitor storage conditions to ensure antibody performance is maintained throughout their experimental timeline.

How can researchers verify SIGLEC7 antibody specificity in their experimental systems?

Verifying antibody specificity is crucial for experimental validity. Researchers should consider multiple approaches: First, compare observed molecular weight with expected values - SIGLEC7 has a calculated molecular weight of 51 kDa (467 amino acids), but typically appears at 65-70 kDa on gels due to post-translational modifications . Second, include appropriate positive controls such as human placenta tissue, human liver tissue, or U-937 cells. Third, consider sialidase treatment as a validation method, as this was used in counter-receptor identification studies and caused band shifting but not disappearance of the target protein . Finally, researchers may employ co-immunoprecipitation followed by immunoblotting with Siglec-7EcFc to confirm specific binding interactions .

How does SIGLEC7 function as an immune checkpoint in cancer immunotherapy research?

SIGLEC7 has been identified as an important inhibitory immune checkpoint that can restrain antitumor immunity. Research demonstrates that Siglec-7 inhibits the endogenous antitumor immune response and can limit the efficacy of tumor-targeting and checkpoint-inhibiting antibodies . The impact of SIGLEC7 on tumor progression is highly dependent on the anatomical distribution of the tumor and the local tumor microenvironment, with more immune-suppressive microenvironments being less sensitive to Siglec perturbation . These findings suggest that SIGLEC7 blockade may represent a promising strategy to augment existing immunotherapies and overcome resistance to T cell-targeting approaches.

What methods have been used to identify SIGLEC7 counter-receptors?

Identification of SIGLEC7 counter-receptors has involved sophisticated biochemical techniques. Researchers purified counter-receptors using affinity chromatography with a Siglec-7 column, where proteins were captured from membrane fractions or whole cell lysates and eluted with either Dex (nonspecific release) or diSia-Dex (specific release) . After electrophoretic separation, bands of interest (notably 110kDa-gp and 270kDa-gp) were excised, subjected to trypsin digestion, and analyzed by LC-mass spectrometry. This approach identified leukosialin (CD43/sialophorin) as a counter-receptor. Confirmation techniques included sialidase treatment to demonstrate sialylation, co-immunoprecipitation, and immunoblotting with Siglec-7EcFc and specific antibodies .

How can researchers develop and characterize SIGLEC7-targeting antibodies for therapeutic applications?

Development of SIGLEC7-targeting antibodies involves multiple methodological approaches. Researchers have generated fully humanized versions of strong Siglec-7 binders by designing codon and RNA-optimized antibody expression cassettes assembled into vectors optimized for human IgG production . Expression can be validated through Western blot analysis and ELISA quantification. To confirm antibody specificity and function, researchers should test their activity in the presence of Fc blockade to demonstrate independence from Fc receptor binding . Additional modifications can include creating variants with multiple residue modifications (e.g., L234F/L235E/P331S) in the Fc domain to ablate FcR and complement binding. Functional validation can be performed through cytotoxicity assays measuring NK-mediated killing of target cells, determining EC50 values, and assessing in vivo efficacy in appropriate mouse models .

How do SIGLEC7 antibodies enhance NK cell-mediated tumor killing?

SIGLEC7 antibodies enhance NK cell-mediated tumor killing by blocking the inhibitory signals delivered through Siglec-7. Studies have demonstrated that anti-Siglec-7 antibodies improved NK-targeted function against ovarian cancer tumor lines, including those containing diverse cancer driver mutations and exhibiting high drug resistance phenotypes . In real-time cell analysis (RTCA), anti-Siglec-7 antibody exhibited 10-fold higher potency than anti-PD-1 in side-by-side assays, highlighting its significant therapeutic potential . The mechanism involves preventing NK cells from receiving negative tumor immune microenvironment signals, thereby unleashing their cytotoxic potential against cancer cells.

What considerations are important for designing NK cell engagers (NKCEs) targeting SIGLEC7?

When designing NK cell engagers (NKCEs) targeting SIGLEC7, researchers should consider several key factors. The construct should be designed to simultaneously engage NK cells through Siglec-7 and cancer targets through tumor-specific antigens such as FSHR in ovarian cancer . Format considerations include using two linked single-chain variable fragments (scFVs), with appropriate flexible linkers (e.g., glycine-serine) between components. For example, the DB7.2xD2AP11 NKCE fusion sequence encoding the scFV of DB7.2 anti-Siglec-7 antibody with the scFV of anti-FSHR (clone D2AP11) proved effective . Validation should include assessing binding specificity to both targets and functional testing to confirm enhanced NK cell activation and target cell killing. The engineered NKCE should demonstrate robust in vitro killing of target-expressing cells and ideally be tested in relevant in vivo models .

How does combination therapy with SIGLEC7 blockade and other checkpoint inhibitors affect antitumor responses?

Combination therapy involving SIGLEC7 blockade and other checkpoint inhibitors shows enhanced efficacy in experimental models. Dual treatment with both anti-PD-1 and anti-Siglec-7 antibodies displayed enhanced ovarian cancer cell killing compared to either agent alone . This synergistic effect suggests that targeting multiple immune checkpoints simultaneously can overcome resistance mechanisms and improve therapeutic outcomes. The complementary mechanisms of action, with PD-1 blockade primarily affecting T cells and Siglec-7 blockade activating NK cells, allows for a more comprehensive immune activation strategy . When designing such combination studies, researchers should carefully assess dosing schedules, potential off-target effects, and the impact of the tumor microenvironment on treatment efficacy.

What factors influence SIGLEC7 antibody efficacy in different experimental systems?

Several factors can influence SIGLEC7 antibody efficacy across experimental systems. Tissue-specificity is a primary consideration, as the impact of Siglec-7 on tumor progression is highly dependent on the anatomical distribution of the tumor and local microenvironment . Sialylation patterns on target cells can also affect Siglec-7 binding, as demonstrated by the altered binding after sialidase treatment in counter-receptor studies . The specific clone and format of the antibody (whole IgG vs. Fab fragments or modified variants) can influence functional outcomes. Additionally, the presence of Fc receptors in the experimental system may contribute to off-target effects, requiring careful consideration of Fc-engineered variants . Researchers should optimize antibody concentration through careful titration in each system, as efficacy can vary significantly between applications and samples .

What are the critical controls needed when using SIGLEC7 antibodies in research applications?

When using SIGLEC7 antibodies, several critical controls should be incorporated to ensure experimental validity. Positive tissue controls should include human placenta tissue, human liver tissue, or U-937 cells, which have been validated for SIGLEC7 expression . Negative controls should include tissues or cells known not to express SIGLEC7 or isotype controls to account for non-specific binding. For functional studies, Fc receptor blocking controls are essential to distinguish specific Siglec-7 engagement from Fc-mediated effects . Researchers investigating sialic acid-dependent binding should include sialidase treatment controls to demonstrate specificity of the interaction . For therapeutic applications, modified antibody variants with mutations in the Fc region (such as DB7.2_TM Mod with L234F/L235E/P331S mutations) should be compared with unmodified versions to isolate the effects of specific Siglec-7 blockade from Fc-dependent mechanisms .